Foretinib (GSK1363089)
|
|
|
- CAS-Nr.
- 849217-64-7
- Englisch Name:
- Foretinib (GSK1363089)
- Synonyma:
- Foretinib;XL880;EXEL-2880;GSK089;GSK 1363089;XL-880,Foretinib;EXEL-2880/XL-880;Foretinib, >=98%;XL880(GSK1363089);Foretinib (XL-880)
- CBNumber:
- CB02490083
- Summenformel:
- C34H34F2N4O6
- Molgewicht:
- 632.65
- MOL-Datei:
- 849217-64-7.mol
|
Foretinib (GSK1363089) Eigenschaften
- Schmelzpunkt:
- >98°C (dec.)
- Siedepunkt:
- 828.5±65.0 °C(Predicted)
- Dichte
- 1.372
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- L?slichkeit
- DMSO (Slightly), Ethanol (Slightly)
- pka
- 13.14±0.70(Predicted)
- Aggregatzustand
- Yellow powder.
- Farbe
- Pale Yellow to Yellow
- CAS Datenbank
- 849217-64-7
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Foretinib (GSK1363089) Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Foretinib is a multikinase inhibitor that targets MET and VEGFR2 and also exhibits an inhibitory effect against KIT, Flt-3, PDGFRb, and Tie-2.
Verwenden
Foretinib (GSK1363089) is an ATP-competitive inhibitor of hepatocyte growth factor (HGF) and Vascular endothelial growth factor (VEGF) Receptor Tyrosine Kinases.
Clinical Use
Foretinib has also shown to be effective against ROS1 mutations especially when acquired with crizotinib resistance. A clinical trial investigating the dosing and safety profile of combining foretinib and erlotinib was designed for advanced pretreated NSCLC patients.
Foretinib (GSK1363089) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Foretinib (GSK1363089) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 227)Lieferanten
- GSK 1363089
- N-[3-Fluoro-4-[[6-(methyloxy)-7-[[3-(morpholin-4-yl)propyl]oxy]quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
- N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
- XL-880,Foretinib
- XL880(GSK1363089)
- FORETINIB GLAXOSMITHKLINE PAPILLARY RENAL CELL CARCINOMA PHASE IIRSCH. TRIANGLE PARK, NC (SEE ALSO HEAD/NECK) (888) 825-5249
- foretinib
N1-{3-fluoro-4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}-N1'-(4-fluorophenyl)-1,1-cyclopropanedicarboxaMide
- Foretinib (GSK1363089, XL880)
- GSK089
- GSK1363089; FORETINIB; EXEL-2880
- Foretinib, Free Base
- EXEL-2880/XL-880
- N-(3-fluoro-4-(6-Methoxy-7-(3-Morpholinopropoxy)quinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxaMide
- N1'-[3-fluoro-4-[[6-Methoxy-7-(3-Morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxaMide
- GSK1363089/foretinib
- N-(3-Fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)-oxy)phenyl)-N-(4-fluorophenyl)cyc
- Foretinib (GSK1363089)
- N-[3-Fluoro-4-[[6-(methyloxy)-7-[[3-(morpholin-4-yl)propyl]oxy]quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1
- Foretinib, >=98%
- Foretinib (XL-880)
- N-(3-Fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)-oxy)phenyl)-N-(4-fluorophenyl)
- 1-N'-[3-FLUORO-4-({6-METHOXY-7-[3-(MORPHOLIN-4-YL)PROPOXY]QUINOLIN-4-YL}OXY)PHENYL]-1-N-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
- Foretinib (XL880,EXEL-2880)
- XL880 (GSK1363089, Foretinib, EXEL-2880)
- XL-880;EXEL-2880;XL 880
- XL-880;GSK089;EXEL-2880;XL 880;GSK-089; GSK 1363089; GSK-1363089
- XL880; XL 880; XL-880; GSK1363089; GSK 1363089; GSK-1363089; GSK089; EXEL2880; FORETINIB.
- 1,1-Cyclopropanedicarboxamide, N-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-
- Foretinib (GSK1363089) USP/EP/BP
- N1'-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinol...
- EXEL-2880
- XL880
- Foretinib, 10 mM in DMSO
- Foretinib
- 849217-64-7
- C34H34F2N4O6
- Inhibitors
